Swedish Orphan Biovitrum AB (publ) Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Investors in Swedish Orphan Biovitrum AB (publ) (STO:SOBI) had a good week, as its shares rose 8.0% to close at kr488 following the release of its quarterly results. The result was positive overall - although revenues of kr9.1b were in line with what the analysts predicted, Swedish Orphan Biovitrum surprised by delivering a statutory profit of kr6.69 per share, modestly greater than expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
After the latest results, the ten analysts covering Swedish Orphan Biovitrum are now predicting revenues of kr38.1b in 2027. If met, this would reflect a decent 19% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to jump 29% to kr24.50. Before this earnings report, the analysts had been forecasting revenues of kr37.5b and earnings per share (EPS) of kr23.75 in 2027. So the consensus seems to have become somewhat more optimistic on Swedish Orphan Biovitrum's earnings potential following these results.
See our latest analysis for Swedish Orphan Biovitrum
The consensus price target was unchanged at kr506, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Swedish Orphan Biovitrum, with the most bullish analyst valuing it at kr600 and the most bearish at kr308 per share. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await Swedish Orphan Biovitrum shareholders.
Of course, another way to look at these forecasts is to place them into context against the industry itself. We can infer from the latest estimates that forecasts expect a continuation of Swedish Orphan Biovitrum'shistorical trends, as the 15% annualised revenue growth to the end of 2027 is roughly in line with the 14% annual growth over the past five years. Juxtapose this against our data, which suggests that other companies (with analyst coverage) in the industry are forecast to see their revenues grow 15% per year. So although Swedish Orphan Biovitrum is expected to maintain its revenue growth rate, it's only growing at about the rate of the wider industry.
The Bottom Line
The biggest takeaway for us is the consensus earnings per share upgrade, which suggests a clear improvement in sentiment around Swedish Orphan Biovitrum's earnings potential next year. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Swedish Orphan Biovitrum going out to 2028, and you can see them free on our platform here..
You can also see whether Swedish Orphan Biovitrum is carrying too much debt, and whether its balance sheet is healthy, for free on our platform here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.